H. Murakami et al., SERUM BETA-2-MICROGLOBULIN IN PATIENTS WITH MULTIPLE-MYELOMA TREATED WITH ALPHA-INTERFERON, Journal of medicine, 28(5-6), 1997, pp. 311-318
Citations number
12
Categorie Soggetti
Medicine, Research & Experimental","Medicine, General & Internal
In ten patients with multiple myeloma (MM), serum beta-2-microglobulin
(B2M) levels were monitored in order to clarify the influence of alph
a interferon (IFN) administration. Despite decreases in M-protein and
the absence of renal dysfunction, the levels of serum B2M were sustain
ed above those prior to melphalan-prednisolone and IFN therapy in seve
n patients with MM for six months. Serum B2M did not increase in ten p
atients with MM treated only by melphalan-prednisolone. Furthermore, s
erum B2M levels in a patient who achieved a complete response were sus
tained above her prior level and returned to normal after cession of I
FN therapy. Our study suggests that the serum B2M level is increased b
y treatment with IFN, and does not prove the condition of the disease.